171 related articles for article (PubMed ID: 29142005)
1. The next step: mechanisms driving adrenocortical carcinoma metastasis.
Lalli E; Luconi M
Endocr Relat Cancer; 2018 Feb; 25(2):R31-R48. PubMed ID: 29142005
[TBL] [Abstract][Full Text] [Related]
2. Surgical management of adrenocortical carcinoma.
Ranvier GG; Inabnet WB
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
[TBL] [Abstract][Full Text] [Related]
3. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management.
Ahmed AA; Thomas AJ; Ganeshan DM; Blair KJ; Lall C; Lee JT; Morshid AI; Habra MA; Elsayes KM
Abdom Radiol (NY); 2020 Apr; 45(4):945-963. PubMed ID: 31894378
[TBL] [Abstract][Full Text] [Related]
4. Late relapse of adrenocortical carcinoma in Beckwith-Wiedemann syndrome. Clinical, endocrinological and genetic aspects.
Hertel NT; Carlsen N; Kerndrup G; Pedersen IL; Clausen N; Hahnemann JM; Jacobsen BB
Acta Paediatr; 2003 Apr; 92(4):439-43. PubMed ID: 12801110
[TBL] [Abstract][Full Text] [Related]
5. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone-producing adrenocortical carcinoma with prominent hepatic metastasis diagnosed by liver biopsy: a case report.
Ohashi K; Hayashi T; Sakamoto M; Iuchi H; Suzuki H; Ebisawa T; Tojo K; Sasano H; Utsunomiya K
BMC Endocr Disord; 2016 Jan; 16():3. PubMed ID: 26772981
[TBL] [Abstract][Full Text] [Related]
7. ENDOCRINE TUMOURS: The genomics of adrenocortical tumors.
Faillot S; Assie G
Eur J Endocrinol; 2016 Jun; 174(6):R249-65. PubMed ID: 26739091
[TBL] [Abstract][Full Text] [Related]
8. Xenograft models for adrenocortical carcinoma.
Hantel C; Beuschlein F
Mol Cell Endocrinol; 2016 Feb; 421():28-33. PubMed ID: 26033247
[TBL] [Abstract][Full Text] [Related]
9. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
10. Advances in understanding the molecular underpinnings of adrenocortical tumors.
Nicolson NG; Man J; Carling T
Curr Opin Oncol; 2018 Jan; 30(1):16-22. PubMed ID: 29028646
[TBL] [Abstract][Full Text] [Related]
11. Metastatic adrenal cortical carcinoma to T12 vertebrae.
Lee D; Yanamadala V; Shankar GM; Shin JH
J Clin Neurosci; 2016 May; 27():166-9. PubMed ID: 26765762
[TBL] [Abstract][Full Text] [Related]
12. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
13. Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma.
Liu-Chittenden Y; Patel D; Gaskins K; Giordano TJ; Assie G; Bertherat J; Kebebew E
J Clin Endocrinol Metab; 2016 Sep; 101(9):3345-52. PubMed ID: 27336360
[TBL] [Abstract][Full Text] [Related]
14. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
15. Complex karyotype in a childhood adrenocortical carcinoma.
Mertens F; Kullendorff CM; Moëll C; Alumets J; Mandahl N
Cancer Genet Cytogenet; 1998 Sep; 105(2):190-2. PubMed ID: 9723041
[TBL] [Abstract][Full Text] [Related]
16. Adrenocortical carcinoma: review and update.
Erickson LA; Rivera M; Zhang J
Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
[TBL] [Abstract][Full Text] [Related]
17. Development of new preclinical models to advance adrenocortical carcinoma research.
Kiseljak-Vassiliades K; Zhang Y; Bagby SM; Kar A; Pozdeyev N; Xu M; Gowan K; Sharma V; Raeburn CD; Albuja-Cruz M; Jones KL; Fishbein L; Schweppe RE; Somerset H; Pitts TM; Leong S; Wierman ME
Endocr Relat Cancer; 2018 Apr; 25(4):437-451. PubMed ID: 29371329
[TBL] [Abstract][Full Text] [Related]
18. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
19. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
